Polysaccharide Vaccines. Current Approaches to Quality Assessment Issues
https://doi.org/10.31631/2073-3046-2020-19-5-104-111
Abstract
Relevance. Polysaccharide vaccine quality assessment must, on the one hand, comply with modern domestic and international regulatory documents, and on the other hand, reflect the characteristics of newly developed drugs. The list of drugs registered on the Russian market is constantly expanding due to the development of new effective vaccines and the introduction of new production sites. Thus, the expert requirements for assessing the quality of these drugs and the information content of the documents submitted as part of the registration dossier need to be updated.
Aims. The aim is to update the expert assessment of quality in preclinical and clinical studies of polysaccharide vaccines, as well as to revise the evaluation of quality parameters depending on the composition and structure of the finished product.
Conclusions. We highlight the key problematic aspects of assessing the protective properties of purified polysaccharides: in particular, the problems related to the natural immunity of animals to diseases caused by bacterial species that are relevant to humans and, as a result, the lack of an adequate experimental model. Modern trends in the characterization and subsequent confirmation of the structure authenticity of purified and conjugated polysaccharides are taken into account. An analysis of the latest international and domestic pharmacopoeial requirements for the quality of polysaccharide vaccines is carried out. The disadvantages of selected methodological approaches to the evaluation of quality parameters such as «Identification» and «Molecular mass distribution» are noted. It is shown that it is necessary to generate recommendations for the examination of polysaccharide vaccines which would unify the recommendations for completing registration dossiers and forming specification files by taking into account each individual peculiarity of this type of drugs.
About the Authors
O. B. Ustinnikova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
Olga В. Ustinnikova – Cand. Sci. (Biol.), head of the laboratory
8 Petrovsky Boulevard, building 2, Moscow, 127051
I. A. Alekseeva
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
Irina А. Alekseeva – expert
8 Petrovsky Boulevard, building 2, Moscow, 127051
M. V. Abramtseva
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
Marina V. Abramtceva – main expert
8 Petrovsky Boulevard, building 2, Moscow, 127051
T. I. Nemirovskaya
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
Tatiana I. Nemirovskaya – Cand. Sci. (Med.), head of the of laboratory
8 Petrovsky Boulevard, building 2, Moscow, 127051
A. A. Movsesyants
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
Artashes A. Movsesyants – Dr. Sci. (Med.), Professor, Head
8 Petrovsky Boulevard, building 2, Moscow, 127051
References
1. Alberts B., Brey D., L’yuis Dzh., et al. Molekular biology of the cell. Moscow: Mir, 1994 (in Russ.).
2. Shipovskaya A.B. Methods of isolation and physical and chemical properties of natural polysaccharides. Educational and methodological guide. Saratovsk. Gosuniversitet, Saratov:, KUBik, 2010 (in Russ.).
3. Kochetkov N.K. Synthesis of polysaccharides. Moscow: Nauka, 1994 (in Russ.).
4. Fel›dblyum I.V., Nikolenko V.V., Vorob›eva N.N., et al. Reaktogennost›, bezopasnost›, immunogennost› i profilakticheskaya effektivnost› polisakharidnoy pnevmokokkovoy vaktsiny pri immunizatsii VICh-infitsirovannykh patsientov. Journal of microbiology epidemiology immunobiology. 2013;3:52 –60 (in Russ).
5. Tarasova G.M., Belov B.S., Bukhanova D.V., et al. Investigation of immunogenicity and safety of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus. Rheumatology Science and Practice. 2018;56(4):433–438 (In Russ.). doi:10.14412/1995-4484-2018-433-438.
6. Bukhanova D.V., Sergeeva M.S., Belov B.S., et al. Immunogenicity and efficiency of a 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results of a 5-year follow up study. Modern Rheumatology Journal. 2018;12(4):85–88 (In Russ.). doi:10.14412/1996-7012-2018-4-85-88.
7. Medunitsyn N.V. Vaccinology. 3rd ed. Moscow: Triada-X; 2010 (in Russ).
8. Fedoseenko M., Galitskaya M., Namazova L. Era of conjugate vaccines: international experience of successful application. Pediatric pharmacology. 2008;5(6):8–14 (in Russ).
9. Titov L.P. Meningococcal infection: current state and problems. Zdravookhranenie. 2010(12):15–23 (in Russ).
10. Rtishchev A.Yu., Koltunov I.E., Petryaykina E.E., Vykhristyuk O.F. Modern opportunities and prospects of vaccination against meningococcal disease in children. Trudnyy patsient, 2017:15(1–2):53–58 (in Russ).
11. http://grls.rosminzdrav.ru/.
12. Order of the Ministry of health of the Russian Federation of 21.03.2014 No. 125n «Ob utverzhdenii natsional’nogo kalendarya profilakticheskikh privivok po epidemicheskim pokazaniyam» Available at: https://www.rospotrebnadzor.ru/deyatelnost/epidemiological-surveillance/?ELEMENT_ID=5575 (in Russ.).
13. Rukovodstvo po provedeniyu doklinicheskikh issledovaniy lekarstvennykh preparatov (immunobiologicheskie lekarstvennye preparaty) Ch. 2. Ed.: Mironov A. N. Moscow: Publication of the Federal state budgetary institution «NCESMP» of the Ministry of health of Russia, 2013.
14. Abramtseva M.V., Tarasov A.P., Nemirovskaya T.I. Meningococcal disease. Polysaccharide meningococcal vaccines. The historical aspects and the current state of vaccine development. Report 2. BIOpreparations. Prevention, Diagnosis, Treatment. 2015;(3):25–33 (In Russ.).
15. Troitskiy V.L. Immunologicheskie osnovy predokhranitel’noy vaktsinatsii protiv dizenterii. Moscow: Medgiz, 1946 (in Russ.).
16. Ratnikov N.N., Akimkin V.G., Azarov I.I., Kovalenko A.N. Evaluation of the effectiveness of vaccination against typhoid fever in an endemic region. M.; Voenno-meditsinskiy zhurnal. 2017;338 (9):41–45 (in Russ.).
17. Alliluev A.P., Dalin M.V., Fish N.G., et al. Method of vi-antigen preparing. Patent RF № RU2135208C1. 27.08.1999 (in Russ.).
18. Szu S.C., Stone A.L., Robbins J.B. Relation between structure and immunologic properties of the Vi capsular polysaccharide. Infect. Immun. 1991;59:4555–4561.
19. Tacket C.O., Ferecio C., Robbins J.B., et al. Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. J. Infect. Dis., 1986; 154:342–346. DOI: 10.1093/infdis/154.2.342.
20. FS.3.3.1.0012.15 Vaktsina bryushnotifoznaya Vi-polisakharidnaya. Gosudarstvennaya Farmakopeya Rossiyskoy Federatsii, izdanie XIV, Ch. 4. M., 2018. Available at: https:// www.femb.ru/ (in Russ).
21. FS.3.3.1.0013.15 Vaktsina dizenteriynaya protiv shigell Zonne polisakharidnaya. Gosudarstvennaya Farmakopeya Rossiyskoy Federatsii, izdanie XIV, Ch. 4. M., 2018. Avail- able at: https://www.femb.ru/ (in Russ).
22. FS.3.3.1.0015.15 Vaktsina meningokokkovaya serogruppy A polisakharidnaya sukhaya. Gosudarstvennaya Farmakopeya Rossiyskoy Federatsii, izdanie XIV, Ch. 4. M., 2018. Available at: https://www.femb.ru/ (in Russ).
23. Typhoid polysaccharide vaccine. 04/2016:1160.
24. Nemirovskaya T.I., Abramtseva M.V., Tarasov A.P., Movsesyants A.A. Development of identification assessment method for meningococcal group A polysaccharide vaccine by ELISA. BIOpreparations. Prevention, Diagnosis, Treatment.; 2013; 2:39-43 (in Russ.).
25. Egan W. Physico-chemical characterization of polysaccharide vaccines. Dev. Biol. (Basel) 2000;103:3–9.
26. Vi Polysaccharide Typhoid Vaccine. Technical Report Series № 840. 1994. Available at: https://apps.who.int/iris/bitstream/handle/10665/39048/WHO_TRS_840_(part1).
27. McCauley J.A., Mancinelli R.J., Downing G.V., Robbins J.B. Molecular size characterization of bacterial capsular polysaccharide vaccines with Sepharose® CL-2B. Journal of Biological Standardizatio. 1981;9(4):461–468.
28. Sadao M., Howard G.B. Size exclusion chromatography. Springer Science & Business Media, 1999:1–5.
29. Requirements for Meningococcal Polysaccharide vaccine. WHO Technical Report Series № 658, 1981. Available at: https://www.who.int/biologicals/technical_report_series/en/
30. Styskin E.L., Itsikson L.B., Braude E.B. Prakticheskaya vysokoeffektivnaya zhidkostnaya khromatografiya. Мoscow: Himia 1986 (in Russ.).
31. Osterman L.A. Khromatografiya belkov i nukleinovykh kislot. Moscow: Nauka. 1985 (in Russ).
32. Khan I., Taufiqur Rahman K.M., Saad Us Siraj S.M., et al. A high-throughput size exclusion chromatography method to determine the molecular size distribution of meningo- coccal polysaccharide vaccine. International Journal of Analytical Chemistry. 2016:1–7. Doi:10.1155/2016/9404068.
33. Macleod C.M., Hodges R.G., Heidelberger M., Bernhard W.G. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. The Journal of Experimental Medicine. 1945;82(6):445–465.
34. Kovtun O.P., Romanenko V.V. Next generation pneumococcal conjugate vaccines efficacy and effectiveness in different regions of the world. Current Pediatrics. 2014;13(1):18– 25 (In Russ.). Doi: 10.15690/vsp.v13i1.908
35. Lee CJ. The quantitative immunochemical determination of pneumococcal and meningococcal capsular polysaccharides by light scattering rate nephelometry. Journal of biological standardization. 1983;11(1):55–64. DOI: 10.1016/s0092-1157(83)80046-8.
36. Verch T., Trausch J.J., Shank-Retzlaff M. Principles of vaccine potency assays. Bioanalysis. 2018;10(3):163–180. DOI: 10.4155/bio-2017-0176.
37. Abeygunawardane С., Williams Т.С., Sunner J.C. Development and validation of an NMR-based identity assay for bacterial polychaccharide. Analytical Biochemistry. 2000; 279(2):226 –240. DOI: 10.1006/abio.1999.4470.
38. Schneerson R., Barrera O., Sutton A., Robbins J.B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide protein conjugates. The Journal of Experimental Medicine. 1980;152:361–376. DOI: 10.1084/jem.152.2.361.
39. Lance K. Gordon. Polysaccharide exotoxoid conjugate vaccine. US Patent № 4,619,828. 8.10.1986.
40. Porter W. Anderson. Immunogenic conjugates. US Patent № 4,673,574.16.06.1987.
41. Stephen Marburg, Richard L. Tolman, Peter J. Kniskern. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and im- munogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency. US Patent № 4,695,624. 22.09.1987.
42. Haemophilus type b and Meningococcal group C conjugate vaccine. 04/2016:2622.
43. Haemophilus type b and conjugate vaccine. 04/2016:1219.
44. Recommendations for the production and control of Haemophilus influenzae type B conjugate vaccine. WHO Technical Report Series No 897. Annex 1 (2000). Available at: https://www.who.int/biologicals/publications/trs/areas/vaccines/haemophilus/en/.
45. Tsai CM, Gu XX, Byrd RA. Quantification of polysaccharide in Haemophilus influenzae type B conjugate and polysaccharide vaccines by high-performance anion-exchange chromatography with pulsed amperometric detection. Vaccine. 1994;12(8):700–706. DOI: 10.1016/0264-410x(94)90219-4.
46. Thiébaud J., Fanget I., Jaudinaud I., et al. Development and validation of high-performance size exclusion chromatography methods to determine molecular size param- eters of Haemophilus influenzae type b polysaccharides and conjugates. Analytical Biochemistry. 2014;453:22–28. DOI: 10.1016/j.ab.2014.02.020.
47. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines. WHO Technical Report Series 927. Annex 2. Available at: https://www.who.int/biologicals/IPV_FINAL_for_BS2233_07072014(2).pdf.
Review
For citations:
Ustinnikova O.B., Alekseeva I.A., Abramtseva M.V., Nemirovskaya T.I., Movsesyants A.A. Polysaccharide Vaccines. Current Approaches to Quality Assessment Issues. Epidemiology and Vaccinal Prevention. 2020;19(5):104-111. (In Russ.) https://doi.org/10.31631/2073-3046-2020-19-5-104-111
Views:
1547
Email this article 